Analyst Price Target is $27.96
▲ +4.33% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Intersect ENT in the last 3 months. The average price target is $27.96, with a high forecast of $32.00 and a low forecast of $23.00. The average price target represents a 4.33% upside from the last price of $26.80.
Current Consensus is
The current consensus among 5 investment analysts is to hold stock in Intersect ENT. This Hold consensus rating has held steady for over two years.
Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. Its products include PROPEL and SINUVA. The PROPEL used to maintain the opening and locally deliver steroid after sinus surgery. The SINUVA is used to treat adult patients with ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.